Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper
- PMID: 38178609
- DOI: 10.1002/ijgo.15278
Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper
Abstract
Menopause marks the end of menstrual cyclicity and, depending on individual vulnerability, has several consequences related to gonadal steroid deprivation, especially if it is premature. Menopause may be more burdensome for some women than for others. Individual factors, such as personal history, socioeconomic status, ethnicity, and current health conditions, affect symptomatology and, thereby, the menopausal experience. In addition, some menopausal symptoms, such as severe hot flashes, sleep disorders, and depression, are markers of future health risks. Counseling is a fundamental part of health care in the peri- and postmenopause periods. It must include an assessment of the patient's symptoms, needs, desires, and risk profile to address the benefits and risks of menopausal hormone therapy (MHT) on an individual basis and promote a healthy lifestyle. Indeed, healthcare practitioners can and must protect the health and lives of mid-life women by increasing awareness of menopausal symptoms and ensuring healthcare options, especially MHT. The type and duration of MHT should be tailored based on the patient's history, menopausal age, physical characteristics, and current health status so that the benefits always outweigh the risks. This FIGO position paper focuses on the benefits and risks of MHT on health domains, target organs, and systems, and on systemic and vaginal MHT regimens, to provide indications that can be used in the clinical practice for menopausal counseling. Moreover, it offers insights into what FIGO considers the mainstay for the healthcare management of women in peri- and postmenopause, worldwide.
Keywords: bioidentical hormones; counseling; hormone therapy; menopausal hormone therapy benefits; menopausal hormone therapy regimens; menopausal hormone therapy risks; menopausal symptoms; menopause.
© 2023 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.
References
REFERENCES
-
- Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause global prevalence, physiology and implications. Nat Rev Endocrinol. 2018;14(4):199-215.
-
- Levine ME, Lu AT, Chen BH, et al. Menopause accelerates biological aging. Proc Natl Acad Sci U S A. 2016;113(33):9327-9332.
-
- Thurston RC, Carroll JE, Levine M, et al. Vasomotor symptoms and accelerated epigenetic aging in the Women's Health Initiative (WHI). J Clin Endocrinol Metab. 2020;105(4):1221-1227.
-
- Ambikairajah A, Walsh E, Cherbuin N. A review of menopause nomenclature. Reprod Health. 2022;19(1):29.
-
- Gibson CJ, Thurston RC, El Khoudary SR, Sutton-Tyrrell K, Matthews KA. Body mass index following natural menopause and hysterectomy with and without bilateral oophorectomy. Int J Obes (Lond). 2013;37(6):809-813.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
